John C. Elkas

John C. Elkas

Oncology | Obstetrics and Gynecology

3580 Joseph Siewick Dr
101
Fairfax, VA 22033

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Journal: Cancer medicine

Published: February 15, 2019

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Journal: Oncotarget

Published: July 01, 2016

Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.

Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.

Journal: The Journal of reproductive medicine

Published: May 14, 2016

We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.

We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.

Journal: Gynecologic oncology

Published: May 03, 2013

Showing 1-4 of 4

Last Updated: 09/26/2026